SIC
CRNX icon

SJS Investment Consulting’s Crinetics Pharmaceuticals CRNX Stock Holding History

SJS Investment Consulting’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38 Buy
+1
New +$37 ﹤0.01% 2775

Other funds holding CRNX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM

SJS Investment Consulting's CRNX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 1 share worth $38. The stake represents ﹤0.01% of the portfolio and ranks #2775 among its holdings.

41 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • SJS Investment Consulting held 1 share of Crinetics Pharmaceuticals worth $38 as of Q2 2026.
  • Crinetics Pharmaceuticals was a new SJS Investment Consulting position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2775 holding.
  • 41 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.